Introduction {#Sec1}
============

Presbyopia is an age-related condition in which the lens of the eye loses elasticity, resulting in inability to focus on near objects. Today, vision impairment due to uncorrected presbyopia is a major cause of disability \[[@CR1], [@CR2]\]. As life expectancy continues to rise in the general population, the prevalence of presbyopia will also likely increase.

The current surgical management of presbyopia generally includes lens procedures in eyes with cataracts and corneal procedures in eyes without cataracts, though other options such as refractive lens extraction may be considered depending on individual ocular characteristics. The latter involves corneal inlays, which are petite optical devices placed within the corneal stroma that function to improve near vision. The small aperture inlay (KAMRA, Acufocus Inc., Irvine, CA, USA) is a type of corneal inlay that has been shown to be effective in the treatment of presbyopia \[[@CR3]--[@CR7]\]. The device is an opaque disk with an outer diameter of 3.8 mm, an inner diameter of 1.6 mm, and a thickness of 5 microns. The aperture takes advantage of pinhole optics by reducing the opening of the eye to increase the depth of focus, thus improving near vision \[[@CR8], [@CR9]\].

Given that presbyopia often occurs during the 5th decade in life, patients who undergo inlay implantation may later develop cataracts, which require surgery. Other than a few case reports, limited published literature exists regarding cataract surgery in patients with a KAMRA inlay \[[@CR10]\]. In this work, we present the visual outcomes of seven patients previously treated with KAMRA inlay, who later underwent phacoemulsification and intraocular lens (IOL) implantation.

Methods {#Sec2}
=======

Seven patients underwent cataract surgery with a previous history of KAMRA inlay implantation. All patients involved were provided written informed consent in accordance with the tenets of the Declaration of Helsinki to having their data used for research purposes. This study was approved by the Hoopes, Durrie, Rivera Internal Review Board. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Regarding KAMRA inlay implantation, a femtosecond laser (150-kHz IntraLase iFS; Abbott Medical Optics Inc) was used for flap creation. Postoperatively, patients were treated with topical ofloxacin 0.3% (Ocuflox, Allergan Inc, Irvine, CA) for 1 week four times daily, prednisolone acetate 1.0% (Pred Forte, Allergan Inc., Irvine, CA) for 1 week four times daily, and fluorometholone 0.1% (FML, Allergan Inc, Irvine, CA) for 3 weeks at a tapering dose starting at four times daily. Regarding cataract surgery, patients underwent optical biometry measurements for intraocular lens (IOL) power calculation via the ZEISS IOLMaster^®^ (Carl Zeiss Meditec, Jena, Germany). All patients underwent phacoemulsification and posterior chamber IOL implantation with the KAMRA inlay left in place.

Case Presentations {#Sec3}
==================

For all seven patients, the uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected near visual acuity (UNVA), and manifest refraction spherical equivalent (MRSE) before and after cataract surgery are shown in Table [1](#Tab1){ref-type="table"}. Postoperatively, UDVA was 20/20 in five (71%) patients and 20/40 or better in seven (100%) patients, while CDVA was 20/20 or better in six (86%) patients and 20/25 in seven (100%) patients. Postoperatively, UNVA was J1 in four (57%) patients, J2 or better in six (86%) patients, and J3 or better in seven (100%) patients. No patients had perioperative complications. Given the similarity between cases, detailed information is provided for three cases, and their overall results are shown in Table [2](#Tab2){ref-type="table"}.Table 1Monocular visual acuity before cataract surgery and at 3 monthsCaseMeasurementBefore cataract surgeryAfter cataract surgery1UDVA20/7020/20CDVA20/4020/20UNVAJ5J2MRSE0.750.1252UDVA20/4020/20CDVA20/3020/15UNVAJ2J1MRSE−0.125−0.753UDVA20/15020/40CDVA20/2520/20UNVAJ1J3MRSE−2.125−0.254UDVA20/3020/30CDVA20/2520/25UNVAJ7J1+MRSE−1.75−0.255UDVA20/15020/20CDVA20/5020/20UNVAJ7J1+MRSE−1.75−0.256UDVA20/3020/20CDVA20/3020/20UNVAJ8J1+MRSE0.25−0.257UDVA20/4020/20CDVA20/2520/20UNVAJ10J2MRSE1.6250.25*UDVA* uncorrected distance visual acuity, *CDVA* corrected distance visual acuity, *UNVA* uncorrected near visual acuity, *MRSE* manifest refraction spherical equivalent Table 2Keratometry, biometry values, biometry method, biometry formula, target power, and power achieved after cataract surgery for three casesMeasurementCase123*K* ~m~ before KAMRA (D)43.745.644.2*K* ~m~ after KAMRA (D)43.645.744.5*K* ~m~ before cataract surgery43.446.044.5AL (mm)23.4922.2323.99Cyl (D)−1.17−0.75−0.82IOL22.0 ZCB0020.5 ZCB0019.5 ZCB00Formula usedHolladay 1SRK/TSRK/TTarget power−0.55−0.85−0.46Achieved power0.125−0.75−0.25*K* average keratometry, *AL* axial length, *Cyl* cylinder, *IOL* intraocular lensIOL MASTER^®^ (Carl Zeiss Meditec, Jena, Germany)

Case 1 {#Sec4}
------

Case one is a 58-year-old white female with no prior ocular surgeries and a history of presbyopia who presented with a non-dominant eye UDVA of 20/15, a CDVA of 20/15, UNVA of J8, and manifest refraction at distance of +0.50 −0.50 × 014 with a near add of +2.25. At the time of surgery, a lamellar flap was created that was 9.5 mm in diameter and 210 microns in depth. The patient had a 3-month postoperative UDVA of 20/15, CDVA of 20/15, UNVA of J2, and manifest refraction at distance of +0.0 −0.50 × 170.

Thirty months after KAMRA inlay implantation, the patient developed a 1+ anterior cortical cataract in the right eye. Sixty months after KAMRA inlay implantation, the patient had a UDVA of 20/70, CDVA of 20/40, UNVA of J5, and manifest refraction of +1.00 −0.50 × 014 (Table [1](#Tab1){ref-type="table"}). At the time of cataract surgery, a 3-mm corneal incision was made at the 9 o'clock position, and an AMO model ZCB00 22.0 diopter lens was then inserted into the capsular bag. The surgeon did not report any changes from his standard surgical technique, the procedure lasted 15 min, and there were no surgical complications. At 3 months postoperatively, the patient had a UDVA of 20/20, CDVA of 20/20, UNVA of J2, and manifest refraction of +0.25 −0.25 × 120 (Table [1](#Tab1){ref-type="table"}). The target power using the Holladay 1 formula was −0.55 D and was most accurate at predicting the achieved power of +0.125, a difference of +0.67 (Table [2](#Tab2){ref-type="table"}). However, SRK/T was also accurate and predicted a power of −0.57, a difference of +0.69.

Case 2 {#Sec5}
------

Case two is a 56-year-old white male with no prior ocular surgeries and a history of presbyopia who presented with non-dominant eye UDVA of 20/15, CDVA of 20/15, UNVA of J8, and manifest refraction of +0.25 −0.50 × 097 and near add of 2.25. At the time of surgery, a lamellar flap was created that was 9.0 mm in diameter and 210 microns in depth. The patient had a 3-month postoperative UDVA of 20/15, CDVA of 20/15, UNVA of J4, and manifest refraction at distance of +0.50 −0.50 × 005.

Fifty-eight months after KAMRA inlay implantation, the patient developed a 1+ anterior cortical cataract in the left eye. Sixty-three months after KAMRA inlay implantation, the patient had a UDVA of 20/40, CDVA of 20/30, UNVA of J2, and manifest refraction at distance of +0.50 −1.25 × 164 (Table [1](#Tab1){ref-type="table"}). At the time of cataract surgery, a 3-mm corneal incision was made at the 3 o'clock position, and an AMO model ZCB00 20.5 diopter lens was then inserted into the capsular bag. The surgeon did not report any changes from his standard surgical technique, the procedure lasted 25 min, and there were no surgical complications. Three months postoperatively, the patient had a UDVA of 20/20, CDVA of 20/15, UNVA of J1, and manifest refraction of −0.75 (Table [1](#Tab1){ref-type="table"}). The target power using the SRK/T was −0.85 D and was most accurate at predicting the achieved power of −0.38, a difference of 0.10 D (Table [2](#Tab2){ref-type="table"}).

Case 3 {#Sec6}
------

Case three is a 56-year-old white male with a no prior ocular surgeries and a history of presbyopia who presented with non-dominant eye UDVA of 20/25, CDVA of 20/15, UNVA of J8, and manifest refraction at distance of +0.25 −0.75 × 146 and near add of 2.25. At the time of surgery, a lamellar flap was created that was 9.5 mm in diameter and 210 microns in depth. The patient had a 3-month postoperative UDVA of 20/20, CDVA of 20/16, UNVA of J1, and manifest refraction at distance of +0.25 −0.75 × 163.

Fifteen months after KAMRA inlay implantation, the patient developed a nuclear sclerotic cataract in the right eye. At 26 months status post KAMRA inlay implantation, the patient had a UDVA of 20/150, CDVA of 20/25, UNVA of J1, and manifest refraction at distance of −1.75 −0.75 × 001 (Table [1](#Tab1){ref-type="table"}). At the time of cataract surgery, a corneal incision was made at the 9 o'clock position, and an AMO model ZCB00 19.5 diopter lens was then inserted into the capsular bag. The surgeon did not report any changes from his standard surgical technique, the procedure lasted 20 min, and there were no surgical complications. At 3 months postoperatively, the patient had a UDVA of 20/40, CDVA of 20/20, UNVA of J3, and manifest refraction at distance of +0.25 −1.00 × 164 (Table [1](#Tab1){ref-type="table"}). The target power using the SRK/T formula was −0.46 D and was most accurate at predicting the achieved power of −0.25, a difference of 0.21 D (Table [2](#Tab2){ref-type="table"}).

Discussion and Conclusions {#Sec7}
==========================

Cataracts and presbyopia are both age-related conditions that cause a decrease in visual acuity. To date, the published literature is limited concerning patients who underwent cataract surgery with a previous history of KAMRA inlay implantation \[[@CR10]\]. As the number of presbyopic patients treated with corneal inlay increases, the number of patients requiring cataract surgery in eyes previously treated with KAMRA inlay will likely increase. This scenario poses several potential concerns for physicians as outlined by Tien-en Tan et al., including poor visual outcomes, inaccuracy of IOL power calculations, and the need to alter the surgical technique secondary to poor visualization \[[@CR10]\].

Poor visual outcomes are a consideration in patients who undergo cataract surgery with a previous history of KAMRA inlay implantation. In this study, visual outcomes were good in all patients after cataract surgery with improvement in both distance and near vision. Postoperatively, all patients had good UDVA, CDVA, and UNVA. Similarly, Tien-en Tan et al. also reported good distance and near visual outcomes after cataract surgery with a mean postoperative UDVA of 20/30, CDVA of 20/25, and UNVA of J2 \[[@CR10]\].

Another possible complication is inaccuracy of the IOL power calculation, which may be affected by changes in keratometry secondary to the previously implanted inlay. In this work, the mean change in keratometry was 0.17 D ± 0.11 (SD) after KAMRA inlay implantation (*n* = 3). This suggests that a negligible change in keratometry occurs after inlay implantation. Furthermore, IOL power calculations were accurate at predicting IOL power after surgery. Three formulas were used to calculate the target IOL power retrospectively, including Haigis, Holladay 1, and SRK/T. In case one, both the Holladay 1 and SRK/T formulae were similar in their prediction of IOL power, and in cases two and three, the SRK/T formula was best at predicting IOL power. The mean target IOL power was −0.62 D ± 0.20 (SD), the mean achieved IOL power was −0.29 D ± 0.44 (SD), and the mean difference in target and achieved IOL power was 0.32 D ± 0.31 (SD) (*n* = 3). Tien-en Tan et al. also found the calculation of IOL power to be accurate. The author reported that the SRK/T formula was the most accurate formula for predicting the achieved power in emmetropic presbyopic patients \[[@CR10]\]. However, the SRK/T formula may not apply to all patients with a previous history of karma inlay implantation who later undergo cataract surgery. A direct comparison of IOL power calculations may be confounded by varying axial length even more than keratometry in the patients evaluated. Given the small patient population in this study, no definitive correlation can be made between axial length and the most accurate formula, and no prior research has addressed which formula is most appropriate with regards to the karma inlay. Thus, we emphasize the need to look at all formulas based on the individual patient.

Regarding the mean difference of +0.3 D between the target and achieved IOL power reported in this study, there may be a tendency toward hyperopic surprise in this patient population. There are many factors that can cause drift in postoperative refraction including effective lens position, changes in biometry, and corneal stromal remodeling changes or inflammation due to the KAMRA inlay itself. To date, however, there is no published literature addressing the possibility of hyperopic shift associated with the karma inlay. Given our small patient sample size, it is difficult to say whether there truly is a trend toward hyperopia. Regardless, our mean difference between target and achieved IOL power falls within the level of accuracy previously reported for cataract surgery in patients without a previous history of karma inlay implantation. Consistent with our outcomes, Shah et al. reported that 77.7% (153 of 197) of eyes undergoing routine cataract surgery had a refractive outcome within 0.5 D of target refraction and 91.4% within 1.0 D without reporting any tendency toward hyperopic shift \[[@CR11]\].

Another potential concern is poor visualization while performing cataract surgery secondary to the KAMRA inlay and the need to alter one's surgical technique. In this work, the mean operating time was 20 min (*n* = 3). Surgeons reported no change to their normal surgical technique other than the need of additional ocular rotations during capsulorhexis and phacoemulsification to improve visualization during surgery. There was a 10-min difference in operative times between case 1 (15 min) and case 2 (25 min). Cataract surgery was performed by a different surgeon in these cases, which may account for the length of each operation. Otherwise, no additional information in the operative reports explains this difference. Similarly to our results, Tien-en Tan et al. reported a mean operating time of approximately 15 min and no significant changes to the regular surgical technique other than additional ocular rotations to improve visualization \[[@CR10]\]. Thus, no significant change in surgical technique appears to be necessary.

In conclusion, cataract surgery is a viable option in patients with a previous history of KAMRA inlay. Our research suggests that visual outcomes after cataract surgery are good with an improvement in near and distance vision. Previous KAMRA inlay implantation results in a negligible change in keratometry and does not affect the accuracy of IOL power calculations. No significant change in surgical technique appears to be needed during uncomplicated cataract surgery. Given our small sample size and the limited amount of published literature regarding cataract surgery following KAMRA inlay implantation, larger studies with longer follow-up are necessary to confirm our observations.
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